@dairegannon.bsky.social
π€ 37
π₯ 42
π 3
Postdoctoral researcher at WEHI
pinned post!
Our work identifying CBX4 as a potential therapeutic target for diffuse midline glioma has just been published in Molecular Cell! Check out co-first author
@eimearlagan.bsky.social
βs overview below.
add a skeleton here at some point
7 months ago
0
7
1
reposted by
Adrian Bracken
2 months ago
1/ π AEBP2 isnβt what we thought. You were told that AEBP2 promotes PRC2 activity on chromatin. We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity. π
surl.li/cgwqcq
A thread π§΅
loading . . .
6
40
18
reposted by
Eric Conway
about 2 months ago
We are delighted that
@genesdev.bsky.social
have selected our (w/
@adrianbracken.bsky.social
) Weaver syndrome paper artwork as the November cover! This piece was made by my incredibly talented niece, Gina 'Dna Vinci' Ronan.
@ucddublin.bsky.social
@tcddublin.bsky.social
@ucd-sbbs.bsky.social
add a skeleton here at some point
1
15
5
reposted by
Australasian Epigenetic Alliance (AEpiA)
2 months ago
Congratulations to the winners of the 2025 AEpiA Emma Whitelaw Publication Award! 𧬠1st place:
@shellainasci.bsky.social
𧬠2nd place:
@victoriasugrue.bsky.social
𧬠3rd place:
@dairegannon.bsky.social
This award recognises outstanding publications by ECRs in the field of epigenetics.
1
13
5
reposted by
Dan Angelov
3 months ago
Absolutely delighted to share our preprint, using functional genomics to uncover a novel dependency in lymphoma that can overcome resistance to targeted therapy. Grateful to co-first author
@jamesnolan.bsky.social
and co-senior authors
@conwayer1.bsky.social
and
@adrianbracken.bsky.social
seeπ
add a skeleton here at some point
0
5
3
reposted by
James Nolan
3 months ago
π§΅1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on
www.biorxiv.org/content/10.1...
. Here's a thread summarizing our findings!π
#CancerResearch
#Epigenetics
#Chromatin
#Lymphoma
loading . . .
AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma
The catalytic subunit of Polycomb Repressive Complex 2 (PRC2), EZH2, is recurrently mutated in 25% of diffuse large B-cell lymphomas (DLBCL), causing increased H3K27me3 and decreased H3K27me2 levels. ...
https://www.biorxiv.org/content/10.1101/2025.10.14.682307v1
1
23
12
Great to see
@jongminkmg.bsky.social
βs preview of our work in
@cp-molcell.bsky.social
today!
www.cell.com/molecular-ce...
loading . . .
Not all CBXs are created equal: A role for the disordered central region of CBX4 in pediatric glioma
In this issue, Lagan et al.1 apply genome-wide and tiling-scan CRISPR screens to uncover a key role for CBX4 and its central region in promoting the growth of diffuse midline glioma cells bearing the ...
https://www.cell.com/molecular-cell/abstract/S1097-2765(25)00455-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1097276525004551%3Fshowall%3Dtrue
7 months ago
1
4
3
reposted by
Molecular Cell
7 months ago
Online Now: A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma Online now:
loading . . .
A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma
Lagan, Gannon, et al. reveal that H3K27M-DMGs depend on a specific form of cPRC1 containing CBX4 and PCGF4. H3K27M alters H3K27me3 distribution, causing increased binding of CBX4-PCGF4-cPRC1 and oncogenic gene repression. CBX4βs ability to read H3K27me3 and to form a specific cPRC1 complex with PCGF4 makes it essential in DMG.
http://dlvr.it/TKvbPC
0
6
5
Our work identifying CBX4 as a potential therapeutic target for diffuse midline glioma has just been published in Molecular Cell! Check out co-first author
@eimearlagan.bsky.social
βs overview below.
add a skeleton here at some point
7 months ago
0
7
1
you reached the end!!
feeds!
log in